Endocrine Abstracts

Oral combined hormonal contraceptives (CHCs) have been suggested to induce more unbeneficial metabolic effects than vaginal CHCs. CHCs are used routinely to treat the clinical symptoms of polycystic ovary syndrome (PCOS), but there are no studies investigating whether the vaginal route is safer in women with known metabolic risks.Twenty-five women with PCOS defined according to the Rotterdam criteria were randomized to use either oral contraceptive pills...

Study question: Does the combination of estradiol valerate (EV) and dienogest (DNG) have favorable effects on inflammation and lipids compared with ethinyl estradiol (EE) + DNG?What is known already: Use of combined oral contraceptives (COCs) increases HDL-cholesterol and triglycerides and promotes low-grade inflammation. The metabolic effects of COCs depend on both estrogen and progestin components. To our knowledge this is the first study comparing COC...

Background: Cardiovascular diseases (CVD) present sex specific characteristics, suggesting sex-hormones playing a role in the pathophysiology of CVDs. Hyperandrogenemia (HA) is a common condition in fertile age women but whether HA is a risk factor for CVD is still controversial.Aims: To clarify the association of HA with the development of hypertension and CVDs in women.Study population and methods: A general population-based birt...

Background: Combined oral contraceptives (COC) are known to have multiple beneficial effects besides contraception, but also cause some unwanted health outcomes. They interfere, for example, with metabolism, inflammation, hepatic protein synthesis and blood coagulation. COCs containing natural estrogens have recently been developed, yet little is known about their non-contraceptive effects compared to conventional COCs with ethinyl estradiol (EE). The aim of this study was to ...

Introduction: Being overweight or obese are common characteristic of women affected by polycystic ovary syndrome (PCOS). Indeed, 50–70% of the women are obese and more likely to present with higher growth rate and obesity already from early childhood compared with women without the syndrome. Obesity predisposes women with PCOS to adverse metabolic outcomes such as metabolic syndrome, insulin resistance and diabetes. Recent studies have also revealed a high prevalence of e...

ObjectiveTo study the predictive value of autoantibodies in progression to type 1 (T1DM) and type 2 (T2DM) diabetes after gestational diabetes (GDM) in a 23-year follow-up study. BackgroundWomen with GDM are at high risk for T2DM later in life, but also the risk of T1DM is increased. We have previously reported a prospective 6-year cohort study showing an association of islet cell and glutamic acid decarboxyl...

ObjectiveTo compare the effects of combined oral contraceptives (COCs) containing estradiol valerate (EV) and dienogest (DNG) with ethinyl estradiol (EE) and DNG on biomarkers of coagulation: thrombin generation (TG), prothrombin fragments F1+2 (F1+2) and D-dimer (D-Di). A DNG-only preparation was included as a control.BackgroundCOC use increases the risk of venous thromboembolism (VTE) 2-6-fold compa...

Background: Women with polycystic ovary syndrome (PCOS) experience increased weight gain during life, thus weight management and preventing weight gain should be the first line treatment. Weight loss is usually self-initiated because practical support for weight management is often limited or even lacking. Perception of overweight is considered an important prerequisite for weight loss attempts, although there is no prior research regarding women with PCOS. The main aim of the...

The significance of hyperandrogenism (HA) as a metabolic risk factor in women is controversial. HA can be defined as either clinical (hirsutism) or biochemical (elevated androgen levels). We aimed to investigate whether HA at age 31 associates with metabolic syndrome (MetS), type 2 diabetes mellitus (DM2) or carotid intima media thickness (CIMT) by age 46. In a prospective, general population-based follow-up birth cohort (n=5889 women) blood samples were collected at ...

Objective: To investigate comorbidity rate, symptoms, overall morbidity, medication useand use of health care services among women with polycystic ovary syndrome (PCOS).Design: Community-based prospective cohort study.Patients: Womenreporting oligo/amenorrhea and hirsutism at age 31 and/or PCOS diagnosis by age 46 (n = 280) and controls without PCOS related symptoms or diagnosis (n = 1573) in the Northern ...